Monograph Details
|
|
Dermatological Disorders
> Psoriasis
|
|
REMICADE |
| Manufacturer |
|
Centocor, Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Tumor necrosis factor-α blocker. |
| Generic Name |
|
Infliximab 100mg/vial; pwd for IV infusion after reconstitution and dilution; preservative-free. |
| Indications |
|
Severe chronic plaque psoriasis in adults who are candidates for systemic therapy and when other systemic therapies are medically less appropriate. |
| Children |
|
Not recommended. |
| Adults |
|
Give by IV infusion over at least 2 hours. 5mg/kg at weeks 0, 2, 6, then once every 8 weeks. |
| Contraindications |
|
Moderate or severe CHF. Clinically important, active infection. Concurrent live vaccines. Allergy to murine proteins. Concurrent anakinra: not recommended. |
| Precautions |
|
Chronic or history of recurring infections or hematological abnormalities. Conditions that predispose to infection. Monitor closely if new infection, reactivation of hepatitis B virus (HBV), or blood dyscrasias develop; discontinue if serious infection, sepsis, HBV reactivation, or hematological abnormality develops. Discontinue if lupus-like syndrome with antibody formation, serious hypersensitivity reactions, or jaundice with liver enzymes ≥5xULN occurs. Mild CHF; discontinue if CHF occurs or worsens. CNS demyelinating or seizure disorders; discontinue if significant CNS effects occur. Malignancies. Test for tuberculosis; treat TB first. Children: complete vaccinations before starting therapy (see literature). Elderly. Pregnancy (Cat.B). Nursing mothers: not recommended. |
| Adverse Reactions |
|
Infection, infusion reactions, headache, GI upset, fatigue, cough, fever, pain, dizziness, rash, pruritus, CHF, antibody formation; rare: malignancies (eg, lymphoma), optic neuritis, seizures, lupus-like syndrome, blood dyscrasias, hepatotoxicity; also children: blood in stool, bone fracture, respiratory tract allergic reaction. |
| How Supplied |
|
Single-use vials—1 |
|
|
|
|
